Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) shares rose after the company reported data from pooled analysis of IGNITE1 and IGNITE4 Phase 3 trials evaluating eravacycline in complicated intra-abdominal infections at the ASM Microbe 2018 Annual Meeting.
The Watertown, Mass.-based Tetraphase, a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, recently reported data on eravacycline, which is currently under review by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of complicated intra-abdominal infections (cIAI), as well as data for TP-6076, its second-generation candidate targeting MDR Gram-negative bacteria, which is currently in phase 1 clinical testing.
These data were presented at the American Society for Microbiology (ASM) Microbe 2018 Annual Meeting, held over the weekend in Atlanta.
CEO Guy Macdonald said, "For the first time, we are sharing a pooled analysis of our IGNITE1 and IGNITE4 studies of eravacycline and are pleased to show that favorable clinical and microbiological responses were observed for eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including those demonstrating resistant phenotypes and genotypes such as MDR and extended spectrum beta-lactamase (ESBL) production."
The primary objective of the pooled analysis was to compare the clinical and microbiological responses at the test-of-cure (TOC) visit for subjects in the two treatment groups, with an emphasis on the response of MDR pathogens to eravacycline.
Tetraphase shares spiked 34 cents, or 9.1%, to $4.08.
Related Stories
